Bristol-Myers Squibb Co.'s Orencia has been approved by the FDA to treat moderate-to-severe polyarticular juvenile idiopathic arthritis in patients over 6 years of age. The clearance is based on the findings of a large trial called AWAKEN, which showed a significant difference between Orencia and a placebo in improving symptoms of the condition.

Related Summaries